Fibrosis is a key factor in IBD progression
Crohn’s Disease (CD)
- 70% of patients develop stricturing/perforating disease
- Stricturing disease is the leading indication for surgery in CD
- The use of anti-inflammatory agents over the past 20 years has not significantly changed the rate of stricturing disease or the need for surgery
- No approved therapies targeting fibrosis and inflammation are available
Ulcerative Colitis (UC)
- While observed at lower rates than in CD, subclinical fibrosis could have significant impact on patient quality of life
- Subclinical fibrosis could contribute to symptoms of diarrhea, abdominal pain, urgency, and incontinence
- Potential explanation for persistent symptoms after the inflammation is resolved